Triple checkpoint blockade of PD-1, Tim-3, and Lag-3 enhances adoptive T cell immunotherapy in a mouse model of ovarian cancer

The five-year survival rate for ovarian cancer patients remains below 50%, underscoring the need for innovative therapies. One promising approach involves engineering T cells to specifically target proteins uniquely overexpressed in tumors, thereby controlling tumor growth without toxicity to health...

Full description

Saved in:

Bibliographic Details
Published in:	Proceedings of the National Academy of Sciences - PNAS Vol. 122; no. 39; p. e2419888122
Main Authors:	Alencar, Gabriel F, Mohamed, Asmaa O, Burnett, Madison G, Jean, Samantha St, Nelson, Anders R, Su, Yapeng, Voillet, Valentin, Bates, Breanna M, Rodgers Suarez, Magdalia, Ruskin, Susan L, Trieu, Lam, Lam, Jennifer L, Bekiranov, Stefan, Gottardo, Raphael, Greenberg, Philip D, Anderson, Kristin G
Format:	Journal Article
Language:	English
Published:	United States 30.09.2025
Subjects:	Animals Antigens, CD - genetics Antigens, CD - immunology Antigens, CD - metabolism Cell Line, Tumor Disease Models, Animal Female Hepatitis A Virus Cellular Receptor 2 - antagonists & inhibitors Hepatitis A Virus Cellular Receptor 2 - immunology Hepatitis A Virus Cellular Receptor 2 - metabolism Humans Immune Checkpoint Inhibitors - pharmacology Immunotherapy, Adoptive - methods Lymphocyte Activation Gene 3 Protein Mesothelin Mice Ovarian Neoplasms - genetics Ovarian Neoplasms - immunology Ovarian Neoplasms - pathology Ovarian Neoplasms - therapy Programmed Cell Death 1 Receptor - antagonists & inhibitors Programmed Cell Death 1 Receptor - immunology T-Lymphocytes - immunology Tumor Microenvironment - immunology checkpoint blockade T cell engineering ovarian cancer adoptive cell therapy immunotherapy
ISSN:	1091-6490, 1091-6490
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!